^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HLA-A underexpression + PD-L1 expression

i
Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
1year
Case #4 (ATS 2023)
Down-regulation of HLA-1 expression is a mechanism of immune-evasion and affects a subset of NSCLC, which abrogates the response to ICI. HLA-1 IHC is an emerging immunomarker in NSCLC and predictor of response to ICI. In addition, we observed that HLA-1 is co-expressed with PD-L1 and represents a surrogate marker of immune-inflamed phenotype which might predict better outcomes to PD(L)-1 blockade.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • CD73 expression • HLA-A underexpression + PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay
1year
Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer (ELCC 2023)
HLA-1 IHC is an emerging immunomarker in NSCLC and predictor of response to ICI. In addition, we observed that HLA-1 is co-expressed with PD-L1 and represents a surrogate marker of immune-inflamed phenotype which might predict better outcomes to PD(L)-1 blockade.
Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • CD73 expression • HLA-A underexpression + PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay